Last update: December 15, 2021
Throughout the ongoing pandemic, we have joined forces to fight COVID-19 in every way possible. This includes developing vaccines at large scales to help prevent and control COVID-19.
"Despite multiple vaccines becoming available, there remain vast global health needs further exasperated by the unpredictability of virus variants. Sanofi is continuing to complement its expertise and resources with that of our peers to help prevent and control the pandemic over the long term."
Paul Hudson, CEO Sanofi
For over a century, vaccines have been a pillar of medical care. Every vaccine developed to date is based upon the same fundamental principle: by teaching our immune systems to recognize a pathogen and destroy it, we can help protect our bodies from infectious diseases. We are building on this principle to develop vaccines against SARS-CoV-2, the coronavirus that causes COVID-19.
The adjuvanted recombinant protein vaccine candidate. In collaboration with the US BARDA, this booster vaccine candidate uses our recombinant protein manufacturing platform together with GSK’s pandemic adjuvant platform. On December 15th, Sanofi and GSK announced positive preliminary results of a study investigating the safety and immune response with their vaccine candidate as a booster regardless of primary vaccine received (mRNA or adenovirus vector based vaccines).
Sanofi continues its ongoing phase 3 trial of the vaccine following a recommendation from the Data Safety and Monitoring Board (DSMB), an independent data oversight body. The DSMB identified no safety concerns and recommended the trial continue into early 2022 to collect and provide the data necessary for regulatory submissions.
In addition to these clinical trials, recently published preclinical data showed that it has the potential to strongly boost immune responses following vaccination with many of the currently approved vaccines and against a broad range of variants.
"All our decisions are and will always be driven by science and data. We remain confident and committed to developing and manufacturing safe and efficacious COVID-19 vaccines."
Thomas Triomphe, Executive Vice President and Head of Sanofi Pasteur
Supporting global supply
We also keep our commitment to making a strong contribution to current global public health priorities by supporting manufacturing and supply of half a billion doses of three different currently approved vaccines: BioNTech’s approved COVID-19 vaccine, co-developed with Pfizer, the vaccine developed by Johnson & Johnson, and the vaccine developed by Moderna.
We are working across multiple countries and in coordination with partner manufacturing sites to make vaccines at the extremely large scales required by the pandemic. The manufacturing process is a complex, never-ending job, but our aim is to supply vaccines to as many people as possible.
